LIST OF TABLES

Table No.	Title	Page No.
3.1	Materials and Equipments- Analytical methods	52
3.2	Calibration for Etoposide in Acetonitrile	55
3.3	Evaluation of accuracy and precision of the estimation method of Etoposide	56
3.4	Calibration for Temozolomide	59
3.5	Evaluation of accuracy and precision of the estimation method of Temozolomide	60
3.6	Calibration for 6-Coumarin in Acetonitrile	63
3.7	Evaluation of accuracy and precision of the estimation method of 6-coumarin	64
3.8	Calibration Curve of PVA (λmax= 690nm)	65
3.9	Preparation of diluted Transferrin standards	67
3.10	Calibration of transferrin by BCA method	68
4.1	Materials and Equipments-Preparation and Transferrin conjugation of nanoparticles	77
4.2	Influence of Stirring Speed	78
4.3	Coded values for the formulation parameters for preparation of nanoparticles	80
4.4	3^3 factorial experimental design for PLGA-ETP-NP	81
4.5	3^3 factorial experimental design for PLGA-TMZ-NP	82
4.6	Analysis of Variance of Full and Reduced Model for PLGA-ETP-NP (PS)	84
4.7	Analysis of Variance of Full and Reduced Model PLGA-ETP-NP (%EE)	85
4.8	Analysis of Variance of Full and Reduced Model PLGA-TMZ-NP (PS)	85
4.9	Analysis of Variance of Full and Reduced Model PLGA-TMZ-NP (%EE)	85
4.10	Check point analysis for PLGA-ETP-NP	93
4.11	Check point analysis for particle size for PLGA-TMZ-NP	93
4.12	Check point analysis for entrapment efficiency for PLGA-TMZ-NP	93
4.13	Effect of different cryoprotectants on the particle size and redispersion	104
4.14	Influence of Concentration of Activating Agent	106
4.15	Influence of amount of Transferrin	109
5.1	Materials and Equipments-Characterization of nanoparticles	118
5.2	Characterization of optimized Tf conjugated and unconjugated PLGA nanoparticles of Etoposide and Temozolomide	122
5.3	Characterization of 6- coumarin nanoparticles	131
6.1	Stability studies data of PLGA-ETP-NP	138

6.2	Stability data of Tf-PLGA-ETP-NP	139
6.3	Stability data of PLGA-TMZ-NP	142
6.4	Stability data of Tf-PLGA-TMZ-NP	144
7.1	Materials and equipments-In-vitro cell culture studies	151
7.2	Influence of Incubation time on the Cellular Uptake Efficiency	156
7.3	Influence of Concentration on the Cellular Uptake Efficiency	157
7.4	Cell viability of Etoposide and Etoposide Nanoparticles	162
7.5	IC50 values for Etoposide and Etoposide Nanoparticles	164
7.6	Cell viability of Temozolomide Solution	165
7.7	Cell viability of Temozolomide and Temozolomide Nanoparticles	165
7.8	IC50 values for Temozolomide and Temozolomide Nanoparticles	168
8.1	Influence of incubation time on the labeling efficiency of ^{99m}Tc-Etoposide formulations	179
8.2	Influence of the Amount of Stannous Chloride on the Labelling Efficiency of Etoposide formulations	179
8.3	Invitro stability of ^{99m}Tc-Etoposide formulations in 0.9%w/v sodium chloride and rat serum at 37°C	180
8.4	Influence of incubation time on the labeling efficiency of ^{99m}Tc-Temozolomide formulations	183
8.5	Influence of the Amount of Stannous Chloride on the Labelling Efficiency of Temozolomide formulations	183
8.6	Invitro stability of ^{99m}Tc-Temozolomide formulations in 0.9%w/v sodium chloride and rat serum at 37°C	184
9.1	Biodistribution of ^{99m}TC labelled ETPS	191
9.2	Biodistribution of ^{99m}TC labelled PLGA-ETP-NP (IV)	191
9.3	Biodistribution of ^{99m}TC labelled Tf-PLGA-ETP-NP	192
9.4	Biodistribution of ^{99m}TC labelled PLGA-ETP-NP (IN)	192
9.5	Pharmacokinetic parameters of Etoposide formulations	194
9.6	AUC values of brain for Etoposide formulations	197
9.7	Biodistribution of ^{99m}Tc labeled TMZS	200
9.8	Biodistribution of ^{99m}Tc labeled PLGA-TMZ-NP (IV)	200
9.9	Biodistribution of ^{99m}Tc labeled Tf-PLGA-TMZ-NP	201
9.10	Biodistribution of ^{99m}Tc labeled PLGA-TMZ-NP (IN)	201
9.11	Pharmacokinetic parameters of Temozolomide formulations	203
9.12	AUC values of brain for Temozolomide formulations	206